Idatha Entsha Ye-Antibody Efudumele Ye-Autoimmune Hemolytic Anemia

A BAMBA MahhalaRelease 4 | eTurboNews | eTN
Isithombe sikaLinda Hohnholz
Ibhalwe ngu Linda Hohnholz

I-Rigel Pharmaceuticals, Inc. namuhla imemezele ukushicilelwa kwedatha ku-American Journal of Hematology kusukela kulebula evulekile, i-multicenter, isifundo somtholampilo seSigaba 2 se-fostamatinib kubantu abadala abane-antibody autoimmune hemolytic anemia (wAIHA) efudumele abahlulekile okungenani ukwelashwa okukodwa kwangaphambili. Idatha eshicilelwe ibonisa ukuthi i-fostamatinib, i-oral spleen tyrosine kinase (SYK) inhibitor, yanda ngokushesha futhi isikhathi eside amazinga e-hemoglobin (Hgb), kanye nezimpendulo ezinengqondo ze-Hgb ezibonwa cishe engxenyeni yeziguli, kanye nephrofayili yokuphepha nokubekezelelana okuhambisanayo Idatha yokuphepha ye-fostamatinib yeziguli kuzo zonke izinhlelo zezifo eziningi ezifundiwe. Ukushicilelwa, okunesihloko esithi “Fostamatinib for the treatment of warm antibody autoimmune hemolytic anemia: Phase 2, multicenter, open-lebel study”, iyatholakala kuwebhusayithi yejenali.

"Imiphumela ephawulwe ocwaningweni lwethu lweSigaba 2 nge-autoimmune hemolytic anemia efudumele iqinisa amandla e-fostamatinib ukusiza iziguli ezinalesi sifo esingavamile, esibucayi segazi okungekho mithi yokwelapha okuhloswe ngayo isifo okwamanje evunyelwe," kusho uRaul Rodriguez, umongameli kanye nesikhulu esiphezulu. isikhulu. "Uma kuvunywa, i-fostamatinib inamandla okuba ukwelashwa kokuqala ukuya emakethe ezigulini ezine-wIHA ngo-2023 futhi kungaba inkomba yesibili egunyaziwe ye-fostamatinib."

Ucwaningo lweSigaba 2 luhlole impendulo ku-fostamatinib ku-150 mg BID (kabili ngosuku) ezigulini ezikhulile ezine-wAIHA kanye ne-hemolysis esebenzayo ene-Hgb engaphansi kuka-10 g/dL ababehlulekile okungenani ukwelashwa okukodwa kwangaphambili. Isiphetho esiyinhloko kwakuyi-Hgb enkulu kuno-10 g/dL ngokunyuka okungu-≥2 g/dL kusukela kwesisekelo ngeviki lama-24 ngaphandle kokwelashwa kokuhlenga noma ukumpontshelwa kwamangqamuzana abomvu egazi. Ucwaningo lubonise ukuthi i-46% (11/24) yeziguli ifinyelele isiphetho esiyinhloko, nomphenduli we-1 sekwephuzile ngesonto lama-30 (inani labaphenduli be-12 [50%]). Ukwenyuka kwe-median Hgb kutholwe evikini lesi-2 futhi kwagcinwa ngokuhamba kwesikhathi. Izehlakalo ezimbi ezivame kakhulu (AEs) kwakuyisifo sohudo (42%), ukukhathala (42%), umfutho wegazi ophakeme (27%), isiyezi (27%), nokuqwasha (23%). Ama-AE ayelawuleka futhi ehambisana nesizindalwazi sokuphepha se-fostamatinib seziguli ezingaphezu kuka-3,900 kuzo zonke izifo eziningi (isifo samathambo, i-B-cell lymphoma, i-COVID-19, ne-immune thrombocytopenia (ITP)). Awekho amasiginali okuphepha amasha atholiwe.

Mayelana umbhali

Isithombe sikaLinda Hohnholz

Linda Hohnholz

Umhleli omkhulu we eTurboNews ezinze eTN HQ.

Bhalisa
Yazisa ngakho
isivakashi
0 Amazwana
Okungaphakathi Okuphakelayo
Buka wonke amazwana
0
Ungathanda imibono yakho, ngicela uphawule.x
Yabelana ku...